ClinicalTrials.gg

TargetBeta

BCL2

BCL2 apoptosis regulator · also Bcl-2, PPP1R50 · Protein phosphatase 1 regulatory subunits

7 programs in company-led studies act on BCL2, from 4 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
venetoclaxruleAbbViephase 48325 running–ChEMBL
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 385 running–the company's pipeline
lacutoclaxruleLupeng Pharmaceuticalphase 243 running–the studies' text
surzetoclaxAbbViephase 233 running–the company's pipeline
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 210 running–the company's pipeline
surzetoclaxAbbViephase 122 running–the company's pipeline
FXS0683Fosun Pharmaphase 111 running–the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.